Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comparison of the Hologic Aptima HIV-1 Quant Dx Assay to the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 for the quantification of HIV-1 RNA in plasma samples

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The challenges of defining sample adequacy in an era of HPV based cervical screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Aseptic meningitis outbreak associated with echovirus 4 in Northern Europe in 2013-2014

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. De novo electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Is oropharyngeal sampling a reliable test to detect SARS-CoV-2?

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: HIV-RNA is the most important parameter for monitoring antiviral treatment in individuals infected with HIV-1. Knowledge of the performance of different tests for the quantification of HIV-1 RNA is therefore important for clinical care.

OBJECTIVES: To compare the analytical performance of the Aptima HIV-1 Quant Dx Assay (Aptima) and the COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 (CAPCTMv2) for the quantification of HIV-1 RNA in plasma samples.

STUDY DESIGN: The performance of the two tests was compared on 216 clinical plasma samples, on dilutions series in seven replicates of five clinical samples of known subtype and on ten replicates of the Acrometrix High and Low Positive Control.

RESULTS: Bland-Altman analysis of 130 samples that quantified in both tests did not show indications of gross mis-quantification of either test. A tendency of the Aptima assay to quantify higher at high viral load compared to the CAPCTMv2 was observed in Bland-Altman analysis, by Deming regression (Slope 1.13) and in dilution series of clinical samples. Precision evaluated using the Acrometrix Positive Controls was similar for the High Control (CV: 1.2% vs. 1.3%; Aptima assay vs. CAPCTMv2 test, respectively), but differed for the Low control (CV: 17.9% vs. 7.1%; Aptima assay vs. CAPCTMv2 test, respectively). However, this did not impact clinical categorization of clinical samples at neither the 50 cp/mL nor 200 cp/mL level.

CONCLUSION: The Aptima assay and the CAPCTMv2 test are highly correlated and are useful for monitoring HIV-infected individuals.

OriginalsprogEngelsk
TidsskriftJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Vol/bind92
Sider (fra-til)14-19
ISSN1386-6532
DOI
StatusUdgivet - 1 maj 2017

ID: 50563570